Monday , November 23 2020

The First Human Human Gammora Drug Clinical Trial offers Cure Potential



Israel's biotechnology company specializing in HIV and cancer treatments has released the results of its first clinical trial of Gammora HIV drugs and the news brings new hope to the person who & They are affected by this destructive retrovirus. It was found that the novel drug was abolished up to 99% of the HIV viruses within four weeks of treatment.

Symptoms that trigger apoptosis

The company called Zion Medical and Gammora is known as an innovative treatment that includes a synthetic peptide compound that is derived from the HIV-based integrase derived from HIV. Entities are enzymes produced by retroviruses, such as HIV, which enables their genetic material to be integrated into the cell DNA's infected.

Taking advantage of this process, Gammora stimulates the integration of multiple HIV DNA pieces into the genomic DNA of the host cells. This, in essence, triggers apoptosis or self-destroying the cell that has been infected.

"These first clinical outcomes were beyond expectations and the pledge hopes to find a cure for discovered disease 35 years, "He said in a statement by Dr. Esmira Naftali, head of development at Medical Check." Given the limited nature of this study, we are proud to prove the efficiency of our drug in Stage 2b with more participants over a longer period of time. "

If this camera proved equally successful its effects would literally change life. Today, the commercially available HIV retroviral treatments work by preventing the spread of the virus but they do not offer any cure for the infection.

As such, HIV patients can only hope for a better life, not a real break. However, Peptide Zion Medical has the potential to destroy all cells that carry the HIV-genome virus that offers real recovery for patients who have been infected.

Phase 1 / 2a Medical Diama Gammora human clinical trial found that most patients showed a significant reduction in the viral load of up to 90% of baseline during the first four weeks. In Part II of the study, Gammora was further combined with extra retroviral treatments that resulted in patients showing up to 99% reduction in viral load of baseline within four weeks.

In addition, throughout the whole 10 weeks From tests, Gammora was found to be safe and tolerant. In fact, no side effects were reported at all.

Promote CD4 cell count

In addition, Gammora was found to promote the patient's CD4 cell count – up to 97% from the baseline. CD4 cells, also referred to T cells or auxiliary cells T cells and cells killed by HIV virus. They are white blood cells that play a key role in the human immune system, the body's natural protective system against pathogens, infections and illness.

As HIV infections develop, CD4 cells are declining. Someone will be diagnosed with AIDS when their numbers fall below 200 and then it will be considered who are at great risk of developing serious illness. To refer to it, the normal range of a healthy individual for CD4 cells is involved 500-1,500.

Zion Medical claims that Gammora "has planned to kill HIV-infected cells without damaging uninfected cells." Its success would change the HIV virus course forever.


Source link